From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Antigen | Product name* (NCT) | Study sponsor | Estimated enrollment | Country |
---|---|---|---|---|
Single-target CAR-T cells | Â | Â | Â | Â |
BCMA | IM21 (NCT04537442) | Beijing Immunochina Medical Science and Technology | 10 | China |
BCMA | CT053 (NCT03975907) | Carsgen | 62 | China |
BCMA | NCT04271644, NCT04272151 | Chongqing Precision Biotech | 80 40 | China |
BCMA | C-CAR088 (NCT03815383) | First Affiliated Hospital with Nanjing Medical University | 12 | China |
BCMA | NCT04626752 | Hebei Senlang Biotechnology | 50 | China |
BCMA | C-CAR088 (NCT03751293) | Hebei Yanda Ludaopei Hospital | 10 | China |
BCMA | NCT04601935 | Nanjing Legend Biotech | 34 | China |
BCMA | C-CAR088 (NCT04295018) | Peking Union Medical College Hospital | 10 | China |
BCMA | NCT04186052 | PersonGen Bio (Suzhou) | 10 | China |
BCMA | C-CAR088 (NCT04322292) | Tianjing Institute of Hematology and Blood Diseases | 10 | China |
BCMA | NCT04637269 | Xinqiao Hospital of Chongqing | 16 | China |
BCMA | CARTBCMA ARI0002h (NCT04309981) | Institut d'Investigacions Biomèdiques August Pi i Sunyer | 36 | Spain |
BCMA | NCT04155749 | Arcelix | 12 | United States |
BCMA | CT053 (NCT03915184) | Carsgen | 70 | United States, Canada |
BCMA | Descartes-11 (NCT03994705) | Cartesian | 18 | United States |
BCMA | CYAD-211 (NCT04613557) | Celyad Oncology | 12 | United States, Belgium |
BCMA | CC-98633 (NCT04394650) | Juno/Celgene | 80 | United States |
BCMA | PHE885 (NCT04318327) | Novartis | 16 | United States |
CD4 | NCT04162340 | iCell Gene Therapeutics | 12 | China |
CD22 | NCT03999697 | PersonGen BioTherapeutics (Suzhou) | 10 | China |
CD44 | MLM-CAR44.1 (NCT04097301) | MolMed S.p.A | 58 | Italy |
CD138 | NCT03672318 | University of North Carolina | 33 | United States |
GPRC5D | MCARH109 (NCT04555551) | Memorial Sloan Kettering Medical Center | 36 | United States |
HA-1 | MDG1021 (NCT04464889) | Medigene | 29 | The Netherlands |
SLAMF7 | NCT04499339 | Wuerzburg University Hospital | 38 | Germany |
SLAMF7 | NCT03958656 | National Cancer Institute | 36 | United States |
TnMUC1 | NCT04025216 | Tmunity | 112 | United States |
Dual-target CAR-T cells | Â | Â | Â | Â |
BCMA CD19 | NCT04194931 | The First Affiliated Hospital of Nanchang University | 20 | China |
BCMA CD19 | NCT04162353 | iCell Gene Therapeutics | 12 | China |
BCMA CD19 | GC012F (NCT04236011) | Shanghai Changzheng Hospital | 15 | China |
BCMA CD19 | NCT04280328 | Xian Xijing Hospital | 18 | China |
BCMA CD19 | NCT04603872 | Zhejiang University | 120 | China |
Universal CAR-T cells | Â | Â | Â | Â |
BCMA | ALLO-715 (NCT04093596) | Allogene | 90 | United States |
BCMA | CTX120 (NCT04244656) | CRISPR Therapeutics | 80 | United States, Australia, Spain |
BCMA | PBCAR269A (NCT04171843) | Precision BioSciences | 48 | United States |
Other | Â | Â | Â | Â |
Anti-BCMA CAR-NK cells | NCT03940833 | Asclepius Technology (Suzhou) | 20 | China |
PD-L1 plus other antigen | NCT04191941 | Timmune Biotech | 9 | China |
CD34 + enriched hematopoietic progenitor cells expressing interferon-ɑ2 | Temferon (NCT03875495) | Genenta | 9 | Italy |
CD8 + T-cells expressing WT1, CD138, NY-ESO-1, and CS1 | NEXI-002 (NCT04505813) | NexImmune | 22 | United States |